Cargando…

Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation

BACKGROUND: Unimpaired HLA class I antigen presentation is a prerequisite for the recognition of tumor cells by cytotoxic T lymphocytes and thus essential for the success of anticancer immunotherapeutic concepts. Several approaches have been taken in the immunotherapy of metastatic renal cell carcin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stickel, Juliane S, Stickel, Natalie, Hennenlotter, Jörg, Klingel, Karin, Stenzl, Arnulf, Rammensee, Hans-Georg, Stevanović, Stefan
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037347/ https://www.ncbi.nlm.nih.gov/pubmed/21251276 http://dx.doi.org/10.1186/1471-2490-11-1

Ejemplares similares

New method of peptide cleavage based on Edman degradation
por: Bąchor, Remigiusz, et al.
Publicado: (2013)

Computer-aided design of a catalyst for Edman degradation utilizing substrate-assisted catalysis
por: Borgo, Benjamin, et al.
Publicado: (2015)

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
por: Reustle, Anna, et al.
Publicado: (2020)

Sensor Array Based Determination of Edman Degradated Amino Acids Using Poly(p‐phenyleneethynylene)s
por: Zhang, Hao, et al.
Publicado: (2020)

Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini
por: Kowalewski, D J, et al.
Publicado: (2016)

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin
por: Kuželová, Kateřina, et al.
Publicado: (2018)

Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome
por: Sturm, Theo, et al.
Publicado: (2020)

LC/MS/MS Analysis of N-Terminal Protein Adducts with Improved Sensitivity: A Comparison of Selected Edman Isothiocyanate Reagents
por: Rydberg, Per, et al.
Publicado: (2009)

Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2021)

The pockets guide to HLA class I molecules
por: Nguyen, Andrea T., et al.
Publicado: (2021)

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
por: Nelde, Annika, et al.
Publicado: (2016)

Fatal Case of Visceral Disease, with Cerebral Symptoms—Post Mortem Examination
por: Stickel, J.
Publicado: (1845)

The Role of Peptides in T Cell Alloreactivity Is Determined by Self–Major Histocompatibility Complex Molecules
por: Obst, Reinhard, et al.
Publicado: (2000)

Cytotoxic T cell recognition of an endogenous class I HLA peptide presented by a class II HLA molecule
Publicado: (1990)

Protein Levels of Anti-Apoptotic Mcl-1 and the Deubiquitinase USP9x Are Cooperatively Upregulated during Prostate Cancer Progression and Limit Response of Prostate Cancer Cells to Radiotherapy
por: Hogh-Binder, Sophia A., et al.
Publicado: (2023)

Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes
por: Sittig, Simone P, et al.
Publicado: (2013)

Evidence of widespread binding of HLA class I molecules to peptides
Publicado: (1990)

HLA Class Ib Molecules and Immune Cells in Pregnancy and Preeclampsia
por: Djurisic, Snezana, et al.
Publicado: (2014)

Surgical approach in patients with T4 bladder cancer as primary treatment: Disaster or option with improved quality of life
por: Nagele, Udo, et al.
Publicado: (2008)

Human Histocompatibility Leukocyte Antigen (HLA)-G Molecules Inhibit NKAT3 Expressing Natural Killer Cells
por: Münz, Christian, et al.
Publicado: (1997)

Evaluation of Hospital-Based Acute Care Utilization by Uninsured Patients Enrolled in Free or Low-Cost Pharmacy Programs
por: Stickel, Jessica, et al.
Publicado: (2021)

HLA ligandome tumor antigen discovery for personalized vaccine approach
por: Rammensee, Hans-Georg, et al.
Publicado: (2013)

HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis
por: Wang, Jian, et al.
Publicado: (2020)

HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy
por: Peper, Janet Kerstin, et al.
Publicado: (2015)

Cell surface expression and function of an HLA class II molecule with class I domain configuration
Publicado: (1993)

The dominantly expressed class II molecule from a resistant MHC haplotype presents only a few Marek’s disease virus peptides by using an unprecedented binding motif
por: Halabi, Samer, et al.
Publicado: (2021)

Oncogenic mutations produce similar phenotypes in Drosophila tissues of diverse origins
por: Stickel, Stefanie, et al.
Publicado: (2014)

HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation
por: Roerden, Malte, et al.
Publicado: (2020)

HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients
por: Tegeler, Christian M., et al.
Publicado: (2022)

Tumor Specific Epigenetic Silencing of Corticotropin Releasing Hormone -Binding Protein in Renal Cell Carcinoma: Association of Hypermethylation and Metastasis
por: Tezval, Hossein, et al.
Publicado: (2016)

Broad Coverage Identification of Multiple Proteolytic Cleavage Site Sequences in Complex High Molecular Weight Proteins Using Quantitative Proteomics as a Complement to Edman Sequencing
por: Doucet, Alain, et al.
Publicado: (2011)

Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study
por: Horstmann, Marcus, et al.
Publicado: (2014)

Assessment of a new point-of-care system for detection of prostate specific antigen
por: Rausch, Steffen, et al.
Publicado: (2016)

Reduced mrna expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer
por: Tezval, Hossein, et al.
Publicado: (2013)

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2018)

Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer
por: Russo, Giorgio Ivan, et al.
Publicado: (2019)

Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases
por: Maas, Moritz, et al.
Publicado: (2023)

ISO Surveys of a Dusty Universe
por: Lemke, D, et al.
Publicado: (1999)

Pulmonary Arterial Hypertension: Combination Therapy in Practice
por: Burks, Marsha, et al.
Publicado: (2018)

A two-phase substrate model for enzymatic hydrolysis of lignocellulose: application to batch and continuous reactors
por: Lischeske, James J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vb4dhe983lqb7o4dafnpj84cmk